Patents by Inventor Zhengbin Yao

Zhengbin Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200317793
    Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
    Type: Application
    Filed: May 23, 2017
    Publication date: October 8, 2020
    Inventors: Rachel Patricia MOATE, Alex GODWOOD, Ethan Paul GRANT, Martin Michael Kari SCHWICKART, Carlos CHAVEZ, Meina LIANG, Tomas Mikael MUSTELIN, Zhengbin YAO, Koustubh RANADE
  • Publication number: 20190305348
    Abstract: A method, device and system for controlling a fuel cell and a rail vehicle are provided. The method includes: an operating power of a target object is detected, wherein the target object is powered by at least two fuel cells (S102); when it is detected that the operating power of the target object is lower than a predetermined power, at least one fuel cell is turned off or a cell component in any one or more fuel cells is turned off according to a gas conversion range corresponding to the fuel cell (S104), wherein the gas conversion range is an output power range value, of the fuel cell, corresponding to a preset range value of a hydrogen conversion rate of the fuel cell.
    Type: Application
    Filed: October 25, 2017
    Publication date: October 3, 2019
    Inventors: Donghua WU, Yankun LI, Qing TIAN, Huiqing ZHANG, Chanjuan XIAO, Qingjun HAN, Zhengbin YAO
  • Publication number: 20180334495
    Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic M retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.
    Type: Application
    Filed: December 15, 2017
    Publication date: November 22, 2018
    Inventors: Sek Chung FUNG, Zhengbin YAO
  • Patent number: 9873734
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: January 23, 2018
    Assignee: GENENTECH, INC.
    Inventors: Sek Chung Fung, Kang Li, Zhengbin Yao
  • Patent number: 8956811
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: February 17, 2015
    Assignee: Genentech Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Publication number: 20140335078
    Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5, C6, C7, C8, C9, or C5b-9.
    Type: Application
    Filed: May 6, 2014
    Publication date: November 13, 2014
    Applicant: Genentech, Inc.
    Inventors: Sek Chung Fung, Zhengbin Yao
  • Patent number: 8841994
    Abstract: The present invention discloses an intelligent traffic safety system based on comprehensive state detection and decision method thereof. The intelligent traffic safety system includes a person condition detection unit, a vehicle condition detection unit, a road condition detection unit, an intelligent decision unit, a driver warning unit, a current vehicle mandatory processing unit, a barrier warning unit, a pursuer warning unit and an after-crash warning unit.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: September 23, 2014
    Assignee: Beijing Its-Star Technology Co., Ltd.
    Inventors: Minghang Li, Zhibin Li, Rose Shao, Tao Ma, Zongli Lin, Bin Li, Zhengbin Yao, Jianchao Mou, Ying Li
  • Patent number: 8753625
    Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.
    Type: Grant
    Filed: November 4, 2006
    Date of Patent: June 17, 2014
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Zhengbin Yao
  • Publication number: 20140057288
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Application
    Filed: July 15, 2013
    Publication date: February 27, 2014
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Patent number: 8513388
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: August 20, 2013
    Assignee: Genentech, Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Publication number: 20120142899
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Application
    Filed: June 30, 2011
    Publication date: June 7, 2012
    Applicant: Genentech, Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Patent number: 7994285
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: August 9, 2011
    Assignee: Genentech, Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Publication number: 20110124081
    Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (“NEAT”) receptor, and related compositions and methods.
    Type: Application
    Filed: November 4, 2010
    Publication date: May 26, 2011
    Inventors: Zhengbin Yao, Guanghu Hu, Kang Li, Jianhua Yang
  • Publication number: 20100233186
    Abstract: Isolated receptors for CTLA-8, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to inhibit an immune response.
    Type: Application
    Filed: March 11, 2010
    Publication date: September 16, 2010
    Inventors: ZHENGBIN YAO, MELANIE K. SPRIGGS, WILLIAM C. FANSLOW
  • Patent number: 7754678
    Abstract: The present invention is directed to membrane penetrating peptides useful as in vivo, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: July 13, 2010
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Yong Guo, Clarence C Morse, Zhengbin Yao, George Keesler
  • Publication number: 20100173383
    Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods.
    Type: Application
    Filed: December 11, 2009
    Publication date: July 8, 2010
    Inventors: ZHENGBIN YAO, GUANGHU HU, KANG LI, JIANHUA YANG
  • Publication number: 20090214538
    Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.
    Type: Application
    Filed: November 4, 2006
    Publication date: August 27, 2009
    Inventors: Sek Chung Fung, Zhengbin Yao
  • Publication number: 20090156467
    Abstract: A promoter comprising the isolated promoter region of the human Thymic Stromal Lymphopoietin (TSLP) gene and functional portions of the promoter region having TSLP promoter activity. The promoters are useful for identifying promoter agonists and antagonists that can be used to prevent or treat allergic conditions and autoimmune diseases.
    Type: Application
    Filed: July 27, 2005
    Publication date: June 18, 2009
    Inventors: Zhengbin Yao, Guanghui Hu, Yucheng Li, Kang Li
  • Publication number: 20090068737
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Application
    Filed: September 19, 2007
    Publication date: March 12, 2009
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Publication number: 20090022710
    Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods.
    Type: Application
    Filed: January 18, 2008
    Publication date: January 22, 2009
    Inventors: Zhengbin Yao, Guanghu Hu, Kang Li, Jianhua Yang